Amyloid plaques are a hallmark of Alzheimer’s disease. The interesting thing is, not everyone who develops these plaques gets Alzheimer’s. Answering this question could reveal

The brain’s power generators, mitochondria, could hold the key to Alzheimer’s disease. Understanding them better is also shedding light on the potential of diabetes drugs

K2 Medical Research is recruiting for a Phase 2 trial of Alector and Abbvie’s new experimental Alzheimer’s drug, AL002.  K2 is screening possible trial participants

Long-term care homes are looking for new ways to improve the lives of their residents. Using dogs and dog robots, scientists have found an unlikely

By: Simon Spichak With all the seemingly contradictory headlines, it is hard to tell whether coffee is good or bad for you. This article explores

K2 Med is recruiting for a new Phase 3 trial for Eli Lilly’s new Alzheimer’s drug donanemab. By: Simon Spichak K2 is screening possible trial

When it comes to music and the brain, there is a very special link. By: Simon Spichak When Tony Bennett’s family announced last February that

K2 is recruiting for a new Phase 3 trial for Alzheon’s new drug, which aims to be the first oral disease-modifying therapy for Alzheimer’s. Join

Alzheimer’s kills brain cells. Can we help the brain make new ones? By: Simon Spichak If you scrape your knee or break a bone, new